



Supplementary Materials
Table 1. Patient characteristics of methodological optimization cohort.

Clinical cohort	Methodological
	Number of cases (%)
Controls	4 (100%)
Healthy	1 (25%)
Inflammation	2 (50%)
Non-GCT TC	1 (25%)
tgct patients	11 (100%)
gcnis	1 (9.1%)
s	5 (45.5%)
ns	5 (45.5%)
Mixed	2 (18.2%)
EC	2 (18.2%)
C	-
T	1 (9.1%)

(T)GCT: (testicular) germ cell tumour, TC: testicular cancer, GCNIS: germ cell neoplasia in situ, S: seminoma, NS: non-seminoma, EC: embryonal carcinoma, C: choriocarcinoma, T: teratoma.








Figure 1. Complete patient histories of the remaining patients of the study with both miRNA and STM measurements. Patient with GCNIS not included in figure, since the patient did not undergo orchidectomy. Abbreviations used: STM; serum tumor markers, NS; non-seminoma, S; seminoma, BS; blood sample, Chemo; chemotherapy, LDH; Lactate dehydrogenase, HCG; beta-human chorionic gonadotropin, AFP; alpha-fetoprotein, miRs; miRNAs.